Hypophosphatemia promotes lower rates of muscle ATP synthesis

Dominik H Pesta, Dimitrios N Tsirigotis, Douglas E Befroy, Daniel Caballero, Michael J Jurczak, Yasmeen Rahimi, Gary W Cline, Sylvie Dufour, Andreas L Birkenfeld, Douglas L Rothman, Thomas O Carpenter, Karl Insogna, Kitt Falk Petersen, Clemens Bergwitz, Gerald I Shulman, Dominik H Pesta, Dimitrios N Tsirigotis, Douglas E Befroy, Daniel Caballero, Michael J Jurczak, Yasmeen Rahimi, Gary W Cline, Sylvie Dufour, Andreas L Birkenfeld, Douglas L Rothman, Thomas O Carpenter, Karl Insogna, Kitt Falk Petersen, Clemens Bergwitz, Gerald I Shulman

Abstract

Hypophosphatemia can lead to muscle weakness and respiratory and heart failure, but the mechanism is unknown. To address this question, we noninvasively assessed rates of muscle ATP synthesis in hypophosphatemic mice by using in vivo saturation transfer [31P]-magnetic resonance spectroscopy. By using this approach, we found that basal and insulin-stimulated rates of muscle ATP synthetic flux (VATP) and plasma inorganic phosphate (Pi) were reduced by 50% in mice with diet-induced hypophosphatemia as well as in sodium-dependent Pi transporter solute carrier family 34, member 1 (NaPi2a)-knockout (NaPi2a-/-) mice compared with their wild-type littermate controls. Rates of VATP normalized in both hypophosphatemic groups after restoring plasma Pi concentrations. Furthermore, VATP was directly related to cellular and mitochondrial Pi uptake in L6 and RC13 rodent myocytes and isolated muscle mitochondria. Similar findings were observed in a patient with chronic hypophosphatemia as a result of a mutation in SLC34A3 who had a 50% reduction in both serum Pi content and muscle VATP After oral Pi repletion and normalization of serum Pi levels, muscle VATP completely normalized in the patient. Taken together, these data support the hypothesis that decreased muscle ATP synthesis, in part, may be caused by low blood Pi concentrations, which may explain some aspects of muscle weakness observed in patients with hypophosphatemia.-Pesta, D. H., Tsirigotis, D. N., Befroy, D. E., Caballero, D., Jurczak, M. J., Rahimi, Y., Cline, G. W., Dufour, S., Birkenfeld, A. L., Rothman, D. L., Carpenter, T. O., Insogna, K., Petersen, K. F., Bergwitz, C., Shulman, G. I. Hypophosphatemia promotes lower rates of muscle ATP synthesis.

Keywords: [31P]MRS; inorganic phosphate; saturation transfer.

© The Author(s).

Figures

Figure 1.
Figure 1.
NaPi2a−/− mice were studied at age 5–6 mo after receiving LPD (0.02% Pi, 0.6% Ca) or HPD (1.2% Pi, 0.6% Ca) for 10 wk. A) CLAMS was used to determine activity over a period of 72 h for LPD and HPD, which was compared with WT littermate controls on regular chow (RC). Activity was reduced in mice that received LPD and was mostly normalized after administering HPD. B, C) Mice with genetically induced hypophosphatemia (NaPi2a−/−) were hypophosphatemic compared with WT littermate controls (B) and showed reduced VATP determined by ST-[31P]MRS (C). D) Actual muscle ATP concentration measured by LC-MS was decreased in NaPi2a−/− mice compared with WT littermate controls. Plasma Pi levels and VATP normalized to euphosphatemic levels after infusion of a bolus of 25 μmol Pi (B, C), whereas muscle ATP concentration was not changed after infusion (D). All data are means ± sem; n = 5–8 in each group. +P < 0.05, NaPi2a−/− on LPD vs. WT on RC; $P < 0.05, NaPi2a−/− on HPD vs. WT on RC; #P < 0.01, NaPi-2a−/− on LPD vs. HPD; *P < 0.05; **P < 0.01 by double-sided Student’s t test.
Figure 2.
Figure 2.
A) WT mice 12–18 wk old maintained on LPD for 2 wk become hypophosphatemic. Mice received a bolus of 30 μmol Pi (Pi-Inf1), 60 μmol (Pi-Inf2), and saline for control group (NaCl-Inf) while in the magnet. B) VATP determined by ST-[31P]MRS was reduced in LPD mice, was increased in these animals after Pi-Inf1, and further increased after Pi-Inf2 compared with NaCl-infused mice. See Fig. 1 and Table 1 for composition of LPD and regular chow (RC). All data are means ± sem; n = 5–8 in each diet group. *P < 0.05, **P < 0.01 by double-sided Student’s t test.
Figure 3.
Figure 3.
A) In vitro measurement of oxygen flux in isolated skeletal muscle mitochondria of WT and NaPi2a−/− mice increased in a dose-dependent manner upon addition of 1 and 5 mM Pi to medium; however, mitochondrial function per se is not impaired in NaPi2a−/− mice compared with WT. B) Insulin increased VATP in WT but not in NaPi2a−/− mice when mice were infused with 5 mU/kg/min insulin, followed by 3 mU/kg/min of insulin and 12.5 mg/kg/min of 20% glucose at a rate of 2.1 μl/min on the basis of body weight of the animal to maintain euglycemia and hyperinsulinemia during ST-[31P]MRS (hyperinsulinemic-euglycemic clamp). C, D) Plasma glucose (C) and insulin (D) values measured after the experiment were not different between the 2 groups. CIP, oxidative phosphorylation capacity of complex I–related substrates. All data are means ± sem; n = 5–8 in each group. *P < 0.05; **P < 0.01 by double-sided Student’s t test.
Figure 4.
Figure 4.
Muscle Pi concentration and VATP are positively correlated. Shown is a regression analysis of muscle Pi and VATP obtained in WT mice, NaPi2a−/− mice, and NaPi2a−/− mice after continuous Pi infusion (A), in the LPD model before and after Pi infusion (B), and in the patient with hypophosphatemic rickets (C). Pi infusion (Pi-Inf) in panels A, B and oral phosphate supplementation after 5 (Rx1) and 8 (Rx2) mo improves VATP in all 3 models. Shown are individual animals with regression lines for each treatment group. Pooled regression analysis of all treatment groups was significant with **P < 0.01 in each panel.
Figure 5.
Figure 5.
An individual with hypophosphatemic rickets has reduced VATP. A) Serum Pi was measured before and again after restoration of hypophosphatemia after a total of 8 mo (Rx2) oral phosphate supplementation with 500 mg KPhos MF 3 times/d, which comprised a total daily dose of 1500 mg. B) VATP was measured before, after 5 mo (Rx1), and again after a total of 8 mo (Rx2) treatment. The patient had reduced VATP measured by ST-[31P]MRS before treatment compared with 5 healthy controls, but VATP was restored after 8 mo treatment. All data are means ± sem; n = 5 in the control group. *P < 0.01 by double-sided Student’s t test.

References

    1. Berndt T., Kumar R. (2007) Phosphatonins and the regulation of phosphate homeostasis. Annu. Rev. Physiol. 69, 341–359
    1. Kuro-o M. (2010) A potential link between phosphate and aging--lessons from Klotho-deficient mice. Mech. Ageing Dev. 131, 270–275
    1. Amanzadeh J., Reilly R. F. Jr (2006) Hypophosphatemia: an evidence-based approach to its clinical consequences and management. Nat. Clin. Pract. Nephrol. 2, 136–148
    1. Camp M. A., Allon M. (1990) Severe hypophosphatemia in hospitalized patients. Miner. Electrolyte Metab. 16, 365–368
    1. Veilleux L. N., Cheung M., Ben Amor M., Rauch F. (2012) Abnormalities in muscle density and muscle function in hypophosphatemic rickets. J. Clin. Endocrinol. Metab. 97, E1492–E1498
    1. Smith R., Newman R. J., Radda G. K., Stokes M., Young A. (1984) Hypophosphataemic osteomalacia and myopathy: studies with nuclear magnetic resonance spectroscopy. Clin. Sci. 67, 505–509
    1. Lardy H. A., Wellman H. (1952) Oxidative phosphorylations; rôle of inorganic phosphate and acceptor systems in control of metabolic rates. J. Biol. Chem. 195, 215–224
    1. Lemasters J. J., Sowers A. E. (1979) Phosphate dependence and atractyloside inhibition of mitochondrial oxidative phosphorylation. The ADP-ATP carrier is rate-limiting. J. Biol. Chem. 254, 1248–1251
    1. Wilson D. F., Stubbs M., Veech R. L., Erecińska M., Krebs H. A. (1974) Equilibrium relations between the oxidation-reduction reactions and the adenosine triphosphate synthesis in suspensions of isolated liver cells. Biochem. J. 140, 57–64
    1. Tager J. M., Wanders R. J., Groen A. K., Kunz W., Bohnensack R., Küster U., Letko G., Böhme G., Duszynski J., Wojtczak L. (1983) Control of mitochondrial respiration. FEBS Lett. 151, 1–9
    1. Khananshvili D., Gromet-Elhanan Z. (1985) Characterization of an inorganic phosphate binding site on the isolated, reconstitutively active. beta. subunit of F0.cntdot.F1 ATP synthase. Biochemistry 24, 2482–2487
    1. Tanaka A., Chance B., Quistorff B. (1989) A possible role of inorganic phosphate as a regulator of oxidative phosphorylation in combined urea synthesis and gluconeogenesis in perfused rat liver. A phosphorus magnetic resonance spectroscopy study. J. Biol. Chem. 264, 10034–10040
    1. Beard D. A. (2006) Modeling of oxygen transport and cellular energetics explains observations on in vivo cardiac energy metabolism. PLOS Comput. Biol. 2, e107.
    1. Segawa H., Aranami F., Kaneko I., Tomoe Y., Miyamoto K. (2009) The roles of Na/Pi-II transporters in phosphate metabolism. Bone 45, S2–S7
    1. Beck L., Leroy C., Beck-Cormier S., Forand A., Salaün C., Paris N., Bernier A., Ureña-Torres P., Prié D., Ollero M., Coulombel L., Friedlander G. (2010) The phosphate transporter PiT1 (Slc20a1) revealed as a new essential gene for mouse liver development. PLoS One 5, e9148
    1. Jensen N., Schrøder H. D., Hejbøl E. K., Füchtbauer E. M., de Oliveira J. R., Pedersen L. (2013) Loss of function of Slc20a2 associated with familial idiopathic basal ganglia calcification in humans causes brain calcifications in mice. J. Mol. Neurosci. 51, 994–999
    1. Lemos R. R., Ramos E. M., Legati A., Nicolas G., Jenkinson E. M., Livingston J. H., Crow Y. J., Campion D., Coppola G., Oliveira J. R. (2015) Update and mutational analysis of SLC20A2: a major cause of primary familial brain calcification. Hum. Mutat. 36, 489–495
    1. Sinha A., Hollingsworth K. G., Ball S., Cheetham T. (2013) Improving the vitamin D status of vitamin D deficient adults is associated with improved mitochondrial oxidative function in skeletal muscle. J. Clin. Endocrinol. Metab. 98, E509–E513
    1. Choi C. S., Befroy D. E., Codella R., Kim S., Reznick R. M., Hwang Y. J., Liu Z. X., Lee H. Y., Distefano A., Samuel V. T., Zhang D., Cline G. W., Handschin C., Lin J., Petersen K. F., Spiegelman B. M., Shulman G. I. (2008) Paradoxical effects of increased expression of PGC-1alpha on muscle mitochondrial function and insulin-stimulated muscle glucose metabolism. Proc. Natl. Acad. Sci. USA 105, 19926–19931
    1. Petersen K. F., Befroy D., Dufour S., Dziura J., Ariyan C., Rothman D. L., DiPietro L., Cline G. W., Shulman G. I. (2003) Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300, 1140–1142
    1. Petersen K. F., Dufour S., Befroy D., Garcia R., Shulman G. I. (2004) Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N. Engl. J. Med. 350, 664–671
    1. Petersen K. F., Dufour S., Shulman G. I. (2005) Decreased insulin-stimulated ATP synthesis and phosphate transport in muscle of insulin-resistant offspring of type 2 diabetic parents. PLoS Med. 2, e233
    1. Hettleman B. D., Sabina R. L., Drezner M. K., Holmes E. W., Swain J. L. (1983) Defective adenosine triphosphate synthesis. An explanation for skeletal muscle dysfunction in phosphate-deficient mice. J. Clin. Invest. 72, 582–589
    1. Jucker B. M., Dufour S., Ren J., Cao X., Previs S. F., Underhill B., Cadman K. S., Shulman G. I. (2000) Assessment of mitochondrial energy coupling in vivo by 13C/31P NMR. Proc. Natl. Acad. Sci. USA 97, 6880–6884
    1. Jucker B. M., Ren J., Dufour S., Cao X., Previs S. F., Cadman K. S., Shulman G. I. (2000) 13C/31P NMR assessment of mitochondrial energy coupling in skeletal muscle of awake fed and fasted rats. Relationship with uncoupling protein 3 expression. J. Biol. Chem. 275, 39279–39286
    1. Lebon V., Dufour S., Petersen K. F., Ren J., Jucker B. M., Slezak L. A., Cline G. W., Rothman D. L., Shulman G. I. (2001) Effect of triiodothyronine on mitochondrial energy coupling in human skeletal muscle. J. Clin. Invest. 108, 733–737
    1. Bergwitz C., Roslin N. M., Tieder M., Loredo-Osti J. C., Bastepe M., Abu-Zahra H., Frappier D., Burkett K., Carpenter T. O., Anderson D., Garabedian M., Sermet I., Fujiwara T. M., Morgan K., Tenenhouse H. S., Juppner H. (2006) SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am. J. Hum. Genet. 78, 179–192
    1. Zhang D., Christianson J., Liu Z. X., Tian L., Choi C. S., Neschen S., Dong J., Wood P. A., Shulman G. I. (2010) Resistance to high-fat diet-induced obesity and insulin resistance in mice with very long-chain acyl-CoA dehydrogenase deficiency. Cell Metab. 11, 402–411
    1. Brooks K. J., Hill M. D., Hockings P. D., Reid D. G. (2004) MRI detects early hindlimb muscle atrophy in Gly93Ala superoxide dismutase-1 (G93A SOD1) transgenic mice, an animal model of familial amyotrophic lateral sclerosis. NMR Biomed. 17, 28–32
    1. Jones A., Tzenova J., Frappier D., Crumley M., Roslin N., Kos C., Tieder M., Langman C., Proesmans W., Carpenter T., Rice A., Anderson D., Morgan K., Fujiwara T., Tenenhouse H. (2001) Hereditary hypophosphatemic rickets with hypercalciuria is not caused by mutations in the Na/Pi cotransporter NPT2 gene. J. Am. Soc. Nephrol. 12, 507–514
    1. Geerse D. A., Bindels A. J., Kuiper M. A., Roos A. N., Spronk P. E., Schultz M. J. (2010) Treatment of hypophosphatemia in the intensive care unit: a review. Crit. Care 14, R147
    1. Soyoral Y., Aslan M., Ebinc S., Dirik Y., Demir C. (2014) Life-threatening hypophosphatemia and/or phosphate depletion in a patient with acute lymphoblastic leukemia: a rare case report. Am. J. Emerg. Med. 32, 1437.e3-e5
    1. Fuller T. J., Carter N. W., Barcenas C., Knochel J. P. (1976) Reversible changes of the muscle cell in experimental phosphorus deficiency. J. Clin. Invest. 57, 1019–1024
    1. Schubert L., DeLuca H. F. (2010) Hypophosphatemia is responsible for skeletal muscle weakness of vitamin D deficiency. Arch. Biochem. Biophys. 500, 157–161
    1. Gravelyn T. R., Brophy N., Siegert C., Peters-Golden M. (1988) Hypophosphatemia-associated respiratory muscle weakness in a general inpatient population. Am. J. Med. 84, 870–876
    1. Imel E. A., Econs M. J. (2012) Approach to the hypophosphatemic patient. J. Clin. Endocrinol. Metab. 97, 696–706
    1. Beck L., Karaplis A. C., Amizuka N., Hewson A. S., Ozawa H., Tenenhouse H. S. (1998) Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc. Natl. Acad. Sci. USA 95, 5372–5377
    1. Haran M., Gross A. (2014) Balancing glycolysis and mitochondrial oxphos: lessons from the hematopoietic system and exercising muscles. Mitochondrion 19 Pt A, 3–7
    1. Cline G. W., Vidal-Puig A. J., Dufour S., Cadman K. S., Lowell B. B., Shulman G. I. (2001) In vivo effects of uncoupling protein-3 gene disruption on mitochondrial energy metabolism. J. Biol. Chem. 276, 20240–20244
    1. Khoshniat S., Bourgine A., Julien M., Weiss P., Guicheux J., Beck L. (2011) The emergence of phosphate as a specific signaling molecule in bone and other cell types in mammals. Cell. Mol. Life Sci. 68, 205–218
    1. Gariballa S. (2008) Refeeding syndrome: a potentially fatal condition but remains underdiagnosed and undertreated. Nutrition 24, 604–606
    1. Andersen H., Nielsen S., Mogensen C. E., Jakobsen J. (2004) Muscle strength in type 2 diabetes. Diabetes 53, 1543–1548
    1. Andreassen C. S., Jakobsen J., Andersen H. (2006) Muscle weakness: a progressive late complication in diabetic distal symmetric polyneuropathy. Diabetes 55, 806–812
    1. Wang C. C., Sorribas V., Sharma G., Levi M., Draznin B. (2007) Insulin attenuates vascular smooth muscle calcification but increases vascular smooth muscle cell phosphate transport. Atherosclerosis 195, e65–e75

Source: PubMed

3
Iratkozz fel